S1P and ATX Modulating Compounds for Demyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelination disorders, such as multiple sclerosis and other autoimmune and inflammatory conditions, are limited in effectiveness, often merely postponing disability rather than providing lasting solutions, and there is a need for new therapeutic approaches that can specifically target S1P and ATX pathways to modulate cellular responses.
Innovation Solution
Development of compounds, represented by formulas (I), (II), and (III), which act as S1P modulating agents and/or ATX modulating agents, specifically as S1P4 antagonists or ATX inhibitors, to selectively target S1P receptors and ATX activity, potentially reducing symptoms of conditions mediated by S1P and ATX activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for demyelination disorders are used, then symptoms may be temporarily managed, but lasting effectiveness is limited and disability is merely postponed
Solution Approach 1:
The patent modifies the chemical structure of S1P and ATX pathway modulators by changing molecular parameters (formulae I, II, III with specific substituents) to achieve superior therapeutic effectiveness and prolonged duration of action compared to conventional treatments. The compounds are designed with specific pharmacological properties that enable sustained modulation of S1P receptors and ATX activity.
Solution Approach 2:
The patent introduces novel intermediary compounds that selectively modulate the S1P and ATX pathways. These compounds act as mediators between the disease pathology and therapeutic response, providing sustained symptom relief through prolonged activation or inhibition of S1P receptors and ATX enzymes, thereby extending the duration of therapeutic action.
2Adaptability or versatility
If existing treatments are used, then some symptom relief is achieved, but they do not specifically target S1P and ATX pathways
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formulae I, II, III) that are selectively active at S1P receptors and ATX enzymes. The compounds exhibit localized pharmacological activity at specific pathway components, providing targeted modulation rather than non-specific symptom relief, thereby improving both pathway specificity and therapeutic effectiveness.
Solution Approach 2:
The patent segments the therapeutic approach by developing separate but complementary compounds targeting S1P receptors and ATX enzymes. This segmentation allows independent optimization of each pathway's modulation, enabling precise control over S1P signaling and ATX activity while maintaining overall therapeutic effectiveness.
3Duration of action of stationary object
If conventional treatments are used, then treatment is provided, but they do not offer lasting solutions for demyelination disorders
Solution Approach 1:
The patent ensures continuity of useful action through compounds that provide sustained modulation of S1P and ATX pathways. The compounds are designed to maintain therapeutic activity over extended periods, eliminating the need for frequent dosing adjustments and providing continuous symptom relief rather than temporary improvement, thereby achieving lasting therapeutic solutions.
Data Source
AI summary
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).